arjungenin

farnesoid X receptor protein agonist

Also Known As:

(2alpha,3beta,19alpha)-2,3,19,24-Tetrahydroxyolean-12-en-28-oic acid; Olean-12-en-28-oic acid, 2,3,19,24-tetrahydroxy-, (2alpha,3beta,19alpha)-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Carcinogenesis 08/01/2013 - "Arjungenin (10) exhibited inhibitory effect on skin-tumor promotion in an in vivo two-stage mouse-skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator and with TPA as promoter. "
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/01/2020 - "Overall, our results suggest that arjungenin and arjunic acid acts as an FXR agonist and may be useful for rational therapeutic strategies as a novel drug to treat cholesterol mediated metabolic syndrome and insulin resistance."
3.	Neoplasms (Cancer) 08/01/2013 - "Arjungenin (10) exhibited inhibitory effect on skin-tumor promotion in an in vivo two-stage mouse-skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator and with TPA as promoter. "
4.	Insulin Resistance 02/01/2020 - "Overall, our results suggest that arjungenin and arjunic acid acts as an FXR agonist and may be useful for rational therapeutic strategies as a novel drug to treat cholesterol mediated metabolic syndrome and insulin resistance."